Edwards Lifesciences (EW) Cash from Financing Activities (2009 - 2026)

Edwards Lifesciences' Cash from Financing Activities history runs 18 years deep, the most recent figure standing at -$451.2 million for Q1 2026.

• In Q1 2026, Cash from Financing Activities fell 74.88% year-over-year to -$451.2 million; the TTM figure through Mar 2026 stood at -$1.2 billion (up 11.72% YoY), while the FY2025 annual figure was -$956.8 million, up 2.67% from the prior year.
• Cash from Financing Activities was -$451.2 million for Q1 2026 at Edwards Lifesciences, down from -$11.4 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $61.7 million in Q1 2024 to a low of -$976.7 million in Q3 2024.
• Historically, Cash from Financing Activities has averaged -$275.7 million across 5 years, with a median of -$206.6 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Cash from Financing Activities plunged 1252.26% in 2022, then soared 154.55% in 2025.
• A 5-year view of Cash from Financing Activities shows it stood at -$838.4 million in 2022, then soared by 50.72% to -$413.2 million in 2023, then surged by 106.92% to $28.6 million in 2024, then slumped by 139.86% to -$11.4 million in 2025, then plunged by 3857.89% to -$451.2 million in 2026.
• The last three Cash from Financing Activities figures came in at -$451.2 million (Q1 2026), -$11.4 million (Q4 2025), and -$740.1 million (Q3 2025), per Business Quant data.